Loading...
NPI 1285308015 · Bay St Louis, MS · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Covenant Laboratories is a clinical medical laboratory provider located in Bay St Louis, Mississippi. This profile covers 84 Medicare and 52 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Covenant Laboratories |
| Address | 290 Hancock Square Dr |
| City | Bay St Louis |
| State | MS |
| ZIP | 39520 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 5, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.6M |
| Medicaid | $350.8K |
COVENANT LABORATORIES is billed to Medicare and Medicaid primarily as a clinical diagnostic laboratory: its top Medicare codes are dominated by definitive and presumptive drug testing (G0483, G0482, G0481, G0480, 80307) and nucleic acid amplification tests (87798, 87631, multiple COVID codes), indicating a service mix focused on high-volume toxicology and infectious-disease molecular diagnostics rather than routine anatomic pathology or outpatient clinical visits. The presence of many amplified probe and multiplex respiratory codes (e.g., 87798, 87631, 87633, 87637) and COVID-specific codes (U0002, U0004, U0005) further signals investment in molecular platforms and high-throughput testing workflows.
Revenue concentration is high on both payers: precomputed Medicare figures show the top 3 Medicare codes account for 64.0% of total Medicare revenue, meaning a small set of tests (notably G0483 and related definitive drug panels) drive most Medicare receipts. On Medicaid the top 3 codes account for 58.5% of total Medicaid revenue, again indicating concentrated revenue streams largely tied to nucleic acid amplification and multiplex respiratory testing. These concentrations suggest the lab’s financial performance is sensitive to volume and reimbursement dynamics for a few high-revenue test types.
Payer mix is Medicare-weighted: lifetime Medicare revenue is reported as $3.6M versus $350.8K in Medicaid, showing Medicare is the dominant source of billed revenue. While both payers are present, the Medicare book of business is an order of magnitude larger than Medicaid, so strategic or contracting changes with Medicare would have outsized impact on overall revenue.
COVENANT LABORATORIES appears to be an established, mid‑tenure NPI registrant: the NPI was enumerated on 2021-08-05 (~5 years ago), which supports that current volumes reflect post‑COVID operational scale-up rather than a brand-new entrant. The timeline aligns with the high volumes seen for COVID-era high-throughput codes such as U0002 (Medicare rank #6 nationally, labeled an "extreme outlier") and U0004/U0005, suggesting the practice ramped molecular testing capacity during the pandemic period.
Competitive standing for key Medicare codes is strong nationally in several areas: G0483 (22+ drug classes) generates $1.3M and ranks #18 of 1063 providers (98th percentile) and 80307 ranks #33 of 4760 providers (99th percentile), both described as "notably above typical national volume." U0002 is an extreme outlier (rank #6 of 1463, 100th percentile) which signals unusually high national volume for that specific COVID diagnostic code. For other common molecular codes like 87798 and 87631 the provider ranks in the 90s percentiles but at lower national positions (e.g., 87798 rank #118 of 1319, 91st percentile), indicating high but not dominant participation.
State-level competitive positioning on Medicaid shows pockets of leadership for specific infectious-disease assays: COVENANT LABORATORIES ranks #1 in-state for 87541 (Legionella) and 87640 (Staphylococcus aureus) and ranks highly for 87798 and 87631 (94th and 83rd percentiles respectively), indicating it is a notable regional supplier of respiratory and pathogen NAAT testing. At the same time, several Medicaid codes (e.g., U0002, 87633, many STI panels) show middle-tier state ranks, so the provider is a market leader for certain targeted assays rather than across all test categories.
The provider’s business model appears to mix high-volume, lower‑unit‑price molecular panels and surveillance assays with mid‑to‑higher unit‑priced definitive toxicology testing: Medicare shows large claim counts for 87798 (13.4K claims, $34 avg) and 80307 (6.3K claims, $61 avg), while definitive GC/MS panels such as G0483 produced the largest share of Medicare revenue ($1.3M, 38.0% of Medicare revenue). This mix explains the revenue concentration noted above and suggests operational emphasis on high-throughput specimen processing plus specialized confirmatory toxicology services.
Statistical outlier labels in the source data underscore operational focus areas rather than random variation: the dataset flags G0483 and 80307 as "notably above typical national volume" and U0002 as an "extreme outlier, far above typical national volume," which corroborates that this provider had unusually high volume for both definitive drug testing and high-throughput COVID testing. Analysts should treat those flagged codes as defining capabilities when benchmarking contract negotiations, network inclusion, or capacity assessments.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
84 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,510 | $240 | $1.3M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,350 | $200 | $458.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 13,410 | $30 | $455.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6,330 | $60 | $386K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,230 | $150 | $188.5K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 3,250 | $30 | $110.4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2,200 | $50 | $109.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 690 | $140 | $96.7K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,120 | $70 | $82.5K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 1,070 | $30 | $36.5K |
Showing 1–10 of 84
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 84 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
52 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 3,580 | $30 | $103.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,630 | $40 | $71.7K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 2,090 | $10 | $20.9K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 620 | $30 | $20.4K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 2,010 | $10 | $20.1K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 2,130 | $10 | $19.2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 660 | $30 | $17.9K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 360 | $30 | $12.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 490 | $10 | $6.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 340 | $10 | $4.1K |
Showing 1–10 of 52
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
52 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 11 | 30 | 240 | $260 | $353.3K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 11 | 20 | 60 | $100 | $124.7K |
| 87536 | A lab tests a patient’s specimen to measure the amount of HIV–1 present. This may be referred to as viral load. | 7 | 10 | 410 | $50 | $115.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 85 | 120 | 1,650 | $30 | $115K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 24 | 20 | 370 | $100 | $114.2K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 103 | 140 | 480 | $60 | $92.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 146 | 230 | 1,870 | $10 | $70.1K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 60 | 110 | 510 | $20 | $70K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 59 | 110 | 490 | $20 | $68.8K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 41 | 90 | 460 | $30 | $63.6K |
Showing 1–10 of 52
Other providers in the same ZIP code as Covenant Laboratories, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.